184 related articles for article (PubMed ID: 27063447)
1. Molecular insight into the differential anti-androgenic activity of resveratrol and its natural analogs: in silico approach to understand biological actions.
Chakraborty S; Kumar A; Butt NA; Zhang L; Williams R; Rimando AM; Biswas PK; Levenson AS
Mol Biosyst; 2016 May; 12(5):1702-9. PubMed ID: 27063447
[TBL] [Abstract][Full Text] [Related]
2. Resveratrol, piceatannol and analogs inhibit activation of both wild-type and T877A mutant androgen receptor.
Lundqvist J; Tringali C; Oskarsson A
J Steroid Biochem Mol Biol; 2017 Nov; 174():161-168. PubMed ID: 28888979
[TBL] [Abstract][Full Text] [Related]
3. Differential effects of resveratrol and its naturally occurring methylether analogs on cell cycle and apoptosis in human androgen-responsive LNCaP cancer cells.
Wang TT; Schoene NW; Kim YS; Mizuno CS; Rimando AM
Mol Nutr Food Res; 2010 Mar; 54(3):335-44. PubMed ID: 20077416
[TBL] [Abstract][Full Text] [Related]
4. Combination of resveratrol and antiandrogen flutamide has synergistic effect on androgen receptor inhibition in prostate cancer cells.
Kai L; Levenson AS
Anticancer Res; 2011 Oct; 31(10):3323-30. PubMed ID: 21965742
[TBL] [Abstract][Full Text] [Related]
5. Study of the impact of the T877A mutation on ligand-induced helix-12 positioning of the androgen receptor resulted in design and synthesis of novel antiandrogens.
Zhou J; Liu B; Geng G; Wu JH
Proteins; 2010 Feb; 78(3):623-37. PubMed ID: 19787772
[TBL] [Abstract][Full Text] [Related]
6. Antiandrogenic activity of resveratrol analogs in prostate cancer LNCaP cells.
Iguchi K; Toyama T; Ito T; Shakui T; Usui S; Oyama M; Iinuma M; Hirano K
J Androl; 2012; 33(6):1208-15. PubMed ID: 22700762
[TBL] [Abstract][Full Text] [Related]
7. The androgen receptor T877A mutant recruits LXXLL and FXXLF peptides differently than wild-type androgen receptor in a time-resolved fluorescence resonance energy transfer assay.
Ozers MS; Marks BD; Gowda K; Kupcho KR; Ervin KM; De Rosier T; Qadir N; Eliason HC; Riddle SM; Shekhani MS
Biochemistry; 2007 Jan; 46(3):683-95. PubMed ID: 17223690
[TBL] [Abstract][Full Text] [Related]
8. Computationally identified novel diphenyl- and phenylpyridine androgen receptor antagonist structures.
Söderholm AA; Viiliäinen J; Lehtovuori PT; Eskelinen H; Roell D; Baniahmad A; Nyrönen TH
J Chem Inf Model; 2008 Sep; 48(9):1882-90. PubMed ID: 18712859
[TBL] [Abstract][Full Text] [Related]
9. Effects of HO-/MeO-PBDEs on androgen receptor: in vitro investigation and helix 12-involved MD simulation.
Wang X; Yang H; Hu X; Zhang X; Zhang Q; Jiang H; Shi W; Yu H
Environ Sci Technol; 2013 Oct; 47(20):11802-9. PubMed ID: 24044724
[TBL] [Abstract][Full Text] [Related]
10. The molecular basis for the inhibition of phosphodiesterase-4D by three natural resveratrol analogs. Isolation, molecular docking, molecular dynamics simulations, binding free energy, and bioassay.
Zhao P; Chen SK; Cai YH; Lu X; Li Z; Cheng YK; Zhang C; Hu X; He X; Luo HB
Biochim Biophys Acta; 2013 Oct; 1834(10):2089-96. PubMed ID: 23871879
[TBL] [Abstract][Full Text] [Related]
11. Antiandrogens prevent stable DNA-binding of the androgen receptor.
Farla P; Hersmus R; Trapman J; Houtsmuller AB
J Cell Sci; 2005 Sep; 118(Pt 18):4187-98. PubMed ID: 16141232
[TBL] [Abstract][Full Text] [Related]
12. Suppression of mutant androgen receptors by flutamide.
Ishioka J; Hara S; Isaacs JT; Tomura A; Nishikawa K; Kageyama Y
Int J Urol; 2009 May; 16(5):516-21. PubMed ID: 19389135
[TBL] [Abstract][Full Text] [Related]
13. A Molecular Modeling Study of the Hydroxyflutamide Resistance Mechanism Induced by Androgen Receptor Mutations.
Liu HL; Zhong HY; Song TQ; Li JZ
Int J Mol Sci; 2017 Aug; 18(9):. PubMed ID: 28832499
[TBL] [Abstract][Full Text] [Related]
14. A novel steroidal antiandrogen targeting wild type and mutant androgen receptors.
Andrieu T; Bertolini R; Nichols SE; Setoud R; Frey FJ; Baker ME; Frey BM
Biochem Pharmacol; 2011 Dec; 82(11):1651-62. PubMed ID: 21907706
[TBL] [Abstract][Full Text] [Related]
15. Antiproliferative effects of resveratrol and the mediating role of resveratrol targeting protein NQO2 in androgen receptor-positive, hormone-non-responsive CWR22Rv1 cells.
Hsieh TC
Anticancer Res; 2009 Aug; 29(8):3011-7. PubMed ID: 19661309
[TBL] [Abstract][Full Text] [Related]
16. Functional analysis of androgen receptor N-terminal and ligand binding domain interacting coregulators in prostate cancer.
Yeh S; Sampson ER; Lee DK; Kim E; Hsu CL; Chen YL; Chang HC; Altuwaijri S; Huang KE; Chang C
J Formos Med Assoc; 2000 Dec; 99(12):885-94. PubMed ID: 11155740
[TBL] [Abstract][Full Text] [Related]
17. Structural Development of Androgen Receptor Antagonists Using Phenylferrocene Framework as a Hydrophobic Pharmacophore.
Ochiai K; Yonezawa R; Fujii S
ChemMedChem; 2024 Mar; 19(6):e202400040. PubMed ID: 38291942
[TBL] [Abstract][Full Text] [Related]
18. Similarities and Distinctions in Actions of Surface-Directed and Classic Androgen Receptor Antagonists.
Suh JH; Chattopadhyay A; Sieglaff DH; Storer Samaniego C; Cox MB; Webb P
PLoS One; 2015; 10(9):e0137103. PubMed ID: 26332122
[TBL] [Abstract][Full Text] [Related]
19. Corepressive function of nuclear receptor coactivator 2 in androgen receptor of prostate cancer cells treated with antiandrogen.
Takeda K; Hara N; Nishiyama T; Tasaki M; Ishizaki F; Tomita Y
BMC Cancer; 2016 May; 16():332. PubMed ID: 27225190
[TBL] [Abstract][Full Text] [Related]
20. Iminoenamine based novel androgen receptor antagonist exhibited anti-prostate cancer activity in androgen independent prostate cancer cells through inhibition of AKT pathway.
Divakar S; Saravanan K; Karthikeyan P; Elancheran R; Kabilan S; Balasubramanian KK; Devi R; Kotoky J; Ramanathan M
Chem Biol Interact; 2017 Sep; 275():22-34. PubMed ID: 28757136
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
